The US has also ordered 3.1 million doses of molnupiravir for around $2.2 billion. Merck – which is developing the drug with Ridgeback Biotherapeutics – is one step ahead for a regulatory ...

The green light means that Paxlovid – based on nirmatrelvir (formerly PF-07321332) and ritonavir – has been cleared for use in the US ahead of rival therapy molnupiravir from Merck & Co and ...

Merck MRK reported fourth-quarter 2024 adjusted ... with $149 million in the previous quarter. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter. The segment generated ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Molnupiravir is under clinical development by Merck and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData, Phase I drugs for Liver Failure (Hepatic Insufficiency) ...

‘it’s a profound game changer’ Merck & Co Inc (NYSE: MRK) reported interim results for the clinical trial of its experimental COVID-19 pill on Friday that showed Molnupiravir reduces ...

Merck has changed since its 2021 spin-off of women's health and biosimilar products in Organon. So far, some of the consequently lost revenues have been compensated by the pandemic-boosted sales of ...

Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...